The Influence of Host Response on Colorectal Cancer Prognosis
Authors:
- Charlotte K. RyanCRCharlotte K. Ryan
- Deepak M. SahasrabudheDSDeepak M. Sahasrabudhe
- Alok A. KhoranaAKAlok A. Khorana
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 4 (1) , 38-45
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinomaCancer, 2003
- SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancerBritish Journal of Cancer, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2001
- The Hallmarks of CancerCell, 2000
- Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009Cancer Immunology, Immunotherapy, 1999
- Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.Journal of Clinical Oncology, 1996
- Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patientsBiomedicine & Pharmacotherapy, 1996
- A Phase II Clinical Trial of Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Colorectal CarcinomaJournal of Immunotherapy, 1994
- Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011JNCI: Journal of the National Cancer Institute, 1988